ATR

AptarGroup, Inc. 10-Q Summary: Quarter Ended June 30, 2008

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2008, for AptarGroup, Inc., a Delaware corporation. The company operates in the packaging components industry, developing and manufacturing consumer product dispensing systems. Operations are organized into three reporting segments: Beauty & Home, Pharma, and Closures. As of July 24, 2008, there were 67,862,004 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17% year-over-year for both the quarter and six-month periods. Approximately 10-11% of this growth was attributed to favorable foreign currency translation (weakening U.S. dollar vs. Euro), with the remainder driven by increased demand for innovative dispensing systems.
• Profitability: Net income rose 22% for the quarter and 23% for the six-month period compared to 2007. Operating income increased 13% for the quarter and 15% for the six-month period.
• Cost Pressures: Cost of sales as a percentage of net sales increased to 67.7% (Q2) and 67.9% (YTD) from 67.4% and 67.1% in the prior year, respectively. This was driven by rising input costs (resin, utilities, transportation), underutilized overhead in the Closures segment, and a higher mix of lower-margin custom tooling sales.
• Segment Performance:
  • Pharma: Sales grew 17% (Q2) and 23% (YTD); Segment income surged 33% (Q2) and 32% (YTD) due to strong demand for nasal spray pumps and better overhead utilization.
  • Beauty & Home: Sales grew 15% (Q2) and 16% (YTD); Segment income grew 2% (Q2) and 7% (YTD), offset by rising input costs.
  • Closures: Sales grew 19% (Q2) and 15% (YTD); however, Segment income declined 4% (Q2) and 12% (YTD) due to resin cost lags and softer demand in household markets.

Guidance, Outlook, and Risks

• Q3 2008 Guidance: Management anticipates diluted earnings per share in the range of $0.55 to $0.58 for the third quarter of 2008.
• Market Outlook: Softer demand is expected in the fragrance/cosmetic and personal care markets in the U.S. and Western Europe due to difficult economic conditions. Pharma sales are expected to remain near Q2 levels, while Closures sales are expected to improve due to new product launches.
• Cost Outlook: Input costs are expected to continue rising in Q3, particularly resin, metal (tinplate/aluminum), and anodization costs. The company's ability to pass these costs to customers will be a key determinant of results.
• Capital Actions:
  • On July 17, 2008, the Board authorized the repurchase of an additional 4 million shares.
  • On July 17, 2008, the quarterly dividend was increased from $0.13 to $0.15 per share.
  • On July 31, 2008, the company refinanced $100 million of short-term borrowings with long-term private placement debt.
• Risks: Key risks include rising material costs, currency exchange rate fluctuations, economic downturns affecting consumer spending, and the successful implementation of a new worldwide ERP system.

Investor Verification Checklist

• Input Cost Pass-Through: Verify the company's ability to offset rising resin and metal costs with price increases in the third quarter.
• Currency Exposure: Monitor the U.S. dollar vs. Euro exchange rate, as a strengthening dollar could negatively impact translated sales and income.
• Pharma Margin Sustainability: Confirm if the elevated profit margins in the Pharma segment (29.6% in Q2) are sustainable or if they will revert to historic levels as management anticipates.
• Capital Expenditures: Review the execution of the estimated $180 million in 2008 capital expenditures, particularly the facility expansion in France and the new ERP system.
• Debt Refinancing: Assess the impact of the July 31, 2008, refinancing of $100 million on future interest expense and liquidity.